Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Presentation TCT 2025

TCT 474: Edoxaban Monotherapy for Atrial Fibrillation and Stable Coronary Artery Disease in Diabetic Patients: The EPIC-CAD Trial

Presenter: Seunghan Lee

October 27, 2025

Presentation AHA 2024

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

Presenter: Chisato Izumi

November 17, 2024

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

Presentation AHA 2023

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial

Presenter: Nina Becher

November 14, 2023

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Presentation TCT 2017

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Pascal Vranckx

November 01, 2017

Presentation TCT 2016

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx

November 01, 2016

Presentation ESC 2016

Edoxaban vs Enoxaparin-Warfarin in Subjects UndergoingCardioversion of Atrial Fibrillation

Presenter: Andreas Goette

August 30, 2016

Presentation TCT 2014

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Michael D. Ezekowitz

September 15, 2014

Presentation

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

Presenter: Robert P. Giugliano

June 24, 2014

Advertisement

TCT 474: Edoxaban Monotherapy for Atrial Fibrillation and Stable Coronary Artery Disease in Diabetic Patients: The EPIC-CAD Trial

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Edoxaban vs Enoxaparin-Warfarin in Subjects UndergoingCardioversion of Atrial Fibrillation

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content